X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SPR206 is a novel, intravenously (IV) administered next-generation polymyxin antibiotic for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by MDR Gram-negative bacterial infections.
Lead Product(s): SPR206
Therapeutic Area: Infections and Infectious Diseases Product Name: SPR206
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2024
Details:
SPR994 (tebipenem pivoxil hydrobromide) is an oral antibiotic which is under phase 3 clinical development for the treatment of patients with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP).
Lead Product(s): Tebipenem Pivoxil Hydrobromide
Therapeutic Area: Infections and Infectious Diseases Product Name: SPR994
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
SPR994 is Spero’s novel late-stage development asset, an oral formulation tablet of tebipenem pivoxil hydrobromide, a carbapenem antibiotic of the β-lactam class.
Lead Product(s): Tebipenem Pivoxil Hydrobromide
Therapeutic Area: Infections and Infectious Diseases Product Name: SPR994
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2023
Details:
Under the terms of the agreement, Spero is responsible for the execution and costs of Phase 3 trial of tebipenem HBr (tebipenem pivoxil hydrobromide), an investigational drug, is being developed as the potentially first oral carbapenem antibiotic for the treatment of cUTI.
Lead Product(s): Tebipenem Pivoxil Hydrobromide
Therapeutic Area: Infections and Infectious Diseases Product Name: Tebipenem HBr
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $591.0 million Upfront Cash: $66.0 million
Deal Type: Licensing Agreement November 08, 2022
Details:
Under the licence agreement, Spero will be responsible for the execution and costs of the remaining phase III trial of tebipenem HBr. GSK will be responsible for the execution and costs of additional clinical development, including regulatory submission and commercialisation.
Lead Product(s): Tebipenem Pivoxil Hydrobromide
Therapeutic Area: Infections and Infectious Diseases Product Name: SPR994
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $816.0 million Upfront Cash: $66.0 million
Deal Type: Licensing Agreement September 22, 2022
Details:
FDA feedback indicates positive results from a single additional Phase 3 clinical trial in patients with complicated urinary tract infection (cUTI), with supportive confirmatory evidence of efficacy could support approval of SPR994 (tebipenem HBr).
Lead Product(s): Tebipenem Pivoxil Hydrobromide
Therapeutic Area: Infections and Infectious Diseases Product Name: SPR994
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Details:
Tebipenem HBr is an investigational drug in the United States being developed for the treatment of cUTI, including pyelonephritis, caused by certain microorganisms, in adult patients who have limited treatment options; tebipenem HBr is not FDA-approved.
Lead Product(s): Tebipenem Pivoxil
Therapeutic Area: Infections and Infectious Diseases Product Name: SPR994
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2022
Details:
SPR994 (tebipenem pivoxil hydrobromide) is Spero’s novel investigational oral formulation of tebipenem, a carbapenem-class antibiotic in japan it is marketed as Orapenem® since 2009 for pediatric infections limited to pneumonia, otitis media and sinusitis.
Lead Product(s): Tebipenem Pivoxil
Therapeutic Area: Infections and Infectious Diseases Product Name: SPR994
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2022
Details:
Tebipenem HBr is an investigational drug in the United States being developed for the treatment of complicated urinary tract infection, including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options.
Lead Product(s): Tebipenem Pivoxil
Therapeutic Area: Infections and Infectious Diseases Product Name: SPR994
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2022
Details:
Oral tebipenem pivoxil hydrobromide, an investigational oral carbapenem antibiotic was noninferior to intravenous ertapenem in the treatment of complicated urinary tract infection and acute pyelonephritis and had a similar safety profile.
Lead Product(s): Tebipenem Pivoxil
Therapeutic Area: Infections and Infectious Diseases Product Name: SPR994
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
